Company: TYRA
Filing Date: 2025-12-01
Form Type: 8-K
Source: 0001193125-25-303162
Chunk: 0

Company: Tyra Biosciences, Inc.
Filing Date: 2025-12-01
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On November 25, 2025, the Board of Directors (the Board) of Tyra Biosciences, Inc. (the Company) appointed Bhavesh Ashar as the Company’s Chief Operating Officer, succeeding Daniel Bensen in that position, who was appointed the Company’s Chief Discovery Officer, each effective as of December 1, 2025.

Mr. Ashar, 60, previously served as Chief Commercial Officer of SpringWorks Therapeutics, Inc. from March 2021 until September 2025, following its acquisition by Merck KGaA in July 2025. From May 2017 to March 2021, Mr. Ashar served as Senior Vice President, General Manager of U. S. Oncology for Bayer. Prior to that, Mr. Ashar served as Vice President, General Manager of U. S. Oncology for Sanofi Genzyme from May 2014 to April 2017 and as Vice President, Global Head of Transplant (Oncology Division) from December 2011 to April 2014, and earlier, held various roles of increasing responsibility at Sanofi Genzyme over an approximately15-yeartenure. Mr. Ashar received a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.

In connection with his appointment, the Company entered into an employment agreement (the Employment Agreement). Under the Employment Agreement, Mr. Ashar’s initial annual base salary will be $550,000. Mr. Ashar will also be eligible to participate in an annual incentive program established by the Board. Mr. Ashar’s target annual incentive compensation under such incentive program will be 40% of his then-applicable annual base salary.

In connection with his commencement of employment, Mr. Ashar will be granted options to purchase 300,000 shares of common stock of the Company pursuant to the Company’s 2021 Incentive Award Plan. The options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the date of grant and the remainder vesting in equal monthly installments over the three years thereafter. The options to be granted to Mr. Ashar will have a ten-yearterm and an exercise price equal to the fair market value of the Company’s common